Concepts (221)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anemia, Sickle Cell | 16 | 2023 | 333 | 2.770 |
Why?
|
| Hydroxyurea | 9 | 2016 | 81 | 1.710 |
Why?
|
| Antisickling Agents | 5 | 2013 | 17 | 1.050 |
Why?
|
| Iron | 5 | 2009 | 263 | 0.810 |
Why?
|
| Fetal Hemoglobin | 4 | 2016 | 28 | 0.750 |
Why?
|
| Polymorphism, Single Nucleotide | 9 | 2024 | 2571 | 0.670 |
Why?
|
| Stroke | 3 | 2023 | 956 | 0.580 |
Why?
|
| Phosphoglycerate Kinase | 2 | 2006 | 7 | 0.540 |
Why?
|
| Anemia, Hemolytic | 2 | 2006 | 31 | 0.530 |
Why?
|
| Mutation, Missense | 3 | 2020 | 826 | 0.520 |
Why?
|
| Exome | 3 | 2017 | 1012 | 0.520 |
Why?
|
| Genetic Variation | 5 | 2024 | 1462 | 0.460 |
Why?
|
| DNA Damage | 5 | 2024 | 516 | 0.430 |
Why?
|
| Pyrophosphatases | 1 | 2013 | 20 | 0.430 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2013 | 63 | 0.430 |
Why?
|
| Erythrocytes | 2 | 2021 | 206 | 0.420 |
Why?
|
| Antimicrobial Cationic Peptides | 3 | 2007 | 33 | 0.420 |
Why?
|
| Membrane Proteins | 2 | 2013 | 1521 | 0.410 |
Why?
|
| Iron Overload | 2 | 2009 | 14 | 0.400 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 2 | 2024 | 49 | 0.400 |
Why?
|
| Micronuclei, Chromosome-Defective | 1 | 2010 | 9 | 0.350 |
Why?
|
| Inflammasomes | 2 | 2022 | 149 | 0.340 |
Why?
|
| Promoter Regions, Genetic | 4 | 2013 | 1354 | 0.340 |
Why?
|
| Sequence Analysis, DNA | 2 | 2016 | 1750 | 0.330 |
Why?
|
| beta-Thalassemia | 1 | 2009 | 27 | 0.330 |
Why?
|
| Genetic Markers | 1 | 2011 | 594 | 0.330 |
Why?
|
| Haplotypes | 3 | 2013 | 510 | 0.320 |
Why?
|
| Nuclear Proteins | 4 | 2024 | 1277 | 0.320 |
Why?
|
| Caspase 2 | 2 | 2024 | 26 | 0.320 |
Why?
|
| Intestinal Absorption | 2 | 2007 | 191 | 0.310 |
Why?
|
| Erythrocyte Transfusion | 1 | 2009 | 122 | 0.300 |
Why?
|
| Mutation | 5 | 2024 | 5735 | 0.290 |
Why?
|
| Genetic Predisposition to Disease | 3 | 2024 | 3045 | 0.280 |
Why?
|
| Genomics | 1 | 2014 | 1461 | 0.280 |
Why?
|
| Liver | 3 | 2009 | 1851 | 0.280 |
Why?
|
| Hemochromatosis | 1 | 2007 | 33 | 0.270 |
Why?
|
| Amidohydrolases | 1 | 2006 | 18 | 0.270 |
Why?
|
| Pyridoxal Kinase | 1 | 2006 | 2 | 0.270 |
Why?
|
| Histocompatibility Antigens Class I | 1 | 2007 | 98 | 0.270 |
Why?
|
| Receptors, Transferrin | 1 | 2006 | 10 | 0.260 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2006 | 65 | 0.260 |
Why?
|
| Child, Preschool | 13 | 2024 | 13781 | 0.250 |
Why?
|
| Gene Expression Regulation | 2 | 2012 | 2535 | 0.250 |
Why?
|
| Child | 16 | 2024 | 24049 | 0.240 |
Why?
|
| Hemolysis | 3 | 2022 | 104 | 0.240 |
Why?
|
| Genome-Wide Association Study | 3 | 2024 | 1629 | 0.240 |
Why?
|
| Alcohol Drinking | 1 | 2007 | 331 | 0.230 |
Why?
|
| UDPglucose-Hexose-1-Phosphate Uridylyltransferase | 1 | 2004 | 3 | 0.230 |
Why?
|
| Gene Transfer Techniques | 1 | 2006 | 374 | 0.230 |
Why?
|
| Antigens, CD | 1 | 2006 | 419 | 0.220 |
Why?
|
| Adolescent | 13 | 2024 | 18929 | 0.220 |
Why?
|
| Wnt Signaling Pathway | 1 | 2024 | 199 | 0.220 |
Why?
|
| Nervous System Diseases | 1 | 2006 | 367 | 0.200 |
Why?
|
| Apoptosis | 2 | 2024 | 1790 | 0.200 |
Why?
|
| Substance-Related Disorders | 1 | 2006 | 456 | 0.200 |
Why?
|
| Humans | 32 | 2024 | 122120 | 0.190 |
Why?
|
| Caspases, Initiator | 1 | 2021 | 6 | 0.190 |
Why?
|
| Cohort Studies | 4 | 2020 | 4633 | 0.190 |
Why?
|
| Inflammation | 3 | 2022 | 1391 | 0.190 |
Why?
|
| Anemia, Hemolytic, Autoimmune | 1 | 2021 | 28 | 0.180 |
Why?
|
| Rh-Hr Blood-Group System | 1 | 2020 | 11 | 0.180 |
Why?
|
| Carrier Proteins | 3 | 2016 | 1015 | 0.180 |
Why?
|
| Brain Ischemia | 1 | 2023 | 258 | 0.180 |
Why?
|
| Caspases | 1 | 2021 | 160 | 0.180 |
Why?
|
| Blood Group Antigens | 1 | 2020 | 69 | 0.170 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2019 | 12 | 0.170 |
Why?
|
| Endothelial Progenitor Cells | 1 | 2019 | 11 | 0.170 |
Why?
|
| Blood Cells | 1 | 2019 | 50 | 0.170 |
Why?
|
| Cell Proliferation | 2 | 2024 | 2311 | 0.170 |
Why?
|
| Drug Resistance | 1 | 2020 | 257 | 0.160 |
Why?
|
| Thrombocytopenia | 1 | 2021 | 230 | 0.160 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2020 | 143 | 0.160 |
Why?
|
| Endothelial Cells | 1 | 2022 | 527 | 0.160 |
Why?
|
| Hepcidins | 3 | 2007 | 20 | 0.160 |
Why?
|
| Chronic Disease | 3 | 2009 | 1165 | 0.160 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2024 | 532 | 0.160 |
Why?
|
| Autoimmune Diseases | 1 | 2021 | 248 | 0.160 |
Why?
|
| Gene Frequency | 3 | 2020 | 703 | 0.150 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2020 | 315 | 0.150 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2012 | 1000 | 0.140 |
Why?
|
| Maximum Tolerated Dose | 2 | 2014 | 157 | 0.140 |
Why?
|
| Macrophages | 1 | 2021 | 610 | 0.140 |
Why?
|
| Genotype | 4 | 2024 | 2524 | 0.130 |
Why?
|
| Transcriptome | 1 | 2022 | 904 | 0.130 |
Why?
|
| Metalloendopeptidases | 1 | 2016 | 95 | 0.130 |
Why?
|
| Male | 15 | 2024 | 59429 | 0.130 |
Why?
|
| Albuminuria | 1 | 2016 | 91 | 0.130 |
Why?
|
| Polymorphism, Genetic | 2 | 2013 | 804 | 0.130 |
Why?
|
| beta-Globins | 2 | 2013 | 6 | 0.120 |
Why?
|
| Glucosephosphate Dehydrogenase | 2 | 2013 | 15 | 0.120 |
Why?
|
| Thrombosis | 1 | 2019 | 515 | 0.120 |
Why?
|
| Female | 14 | 2024 | 64764 | 0.120 |
Why?
|
| Open Reading Frames | 1 | 2014 | 211 | 0.110 |
Why?
|
| Repressor Proteins | 3 | 2016 | 808 | 0.110 |
Why?
|
| Risk Factors | 4 | 2016 | 9864 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 1677 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 2 | 2006 | 1592 | 0.100 |
Why?
|
| Heme | 2 | 2022 | 52 | 0.100 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2011 | 9 | 0.090 |
Why?
|
| RNA | 2 | 2022 | 578 | 0.090 |
Why?
|
| Interleukin-1beta | 2 | 2022 | 160 | 0.090 |
Why?
|
| Mice | 6 | 2024 | 17552 | 0.090 |
Why?
|
| Pharmacogenetics | 1 | 2011 | 180 | 0.090 |
Why?
|
| Micronucleus Tests | 1 | 2010 | 7 | 0.090 |
Why?
|
| Infant | 5 | 2024 | 12304 | 0.090 |
Why?
|
| Transcription Factors | 3 | 2016 | 2579 | 0.090 |
Why?
|
| Brazil | 2 | 2023 | 121 | 0.090 |
Why?
|
| Time | 1 | 2010 | 92 | 0.090 |
Why?
|
| DNA Mutational Analysis | 2 | 2011 | 792 | 0.080 |
Why?
|
| Cytoplasm | 1 | 2009 | 291 | 0.080 |
Why?
|
| Phenotype | 2 | 2016 | 4151 | 0.080 |
Why?
|
| DNA-Binding Proteins | 2 | 2014 | 2028 | 0.080 |
Why?
|
| Signal Transduction | 3 | 2012 | 4511 | 0.080 |
Why?
|
| Adult | 7 | 2023 | 28676 | 0.080 |
Why?
|
| Chromosome Aberrations | 1 | 2011 | 617 | 0.080 |
Why?
|
| Alleles | 3 | 2020 | 1576 | 0.070 |
Why?
|
| Prospective Studies | 2 | 2016 | 5965 | 0.070 |
Why?
|
| Stress, Physiological | 1 | 2009 | 265 | 0.070 |
Why?
|
| Luminescence | 1 | 2007 | 15 | 0.070 |
Why?
|
| Linear Models | 1 | 2009 | 654 | 0.070 |
Why?
|
| Response Elements | 1 | 2007 | 99 | 0.070 |
Why?
|
| Mice, Inbred C57BL | 2 | 2007 | 4366 | 0.070 |
Why?
|
| Mice, Inbred AKR | 1 | 2007 | 12 | 0.070 |
Why?
|
| Hemochromatosis Protein | 1 | 2007 | 22 | 0.070 |
Why?
|
| Endotoxins | 1 | 2007 | 48 | 0.070 |
Why?
|
| Luciferases | 1 | 2007 | 137 | 0.070 |
Why?
|
| Animals | 6 | 2024 | 33724 | 0.070 |
Why?
|
| Spain | 1 | 2006 | 53 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2006 | 138 | 0.070 |
Why?
|
| Solubility | 1 | 2006 | 133 | 0.060 |
Why?
|
| Linkage Disequilibrium | 1 | 2006 | 306 | 0.060 |
Why?
|
| Retinal Degeneration | 1 | 2006 | 92 | 0.060 |
Why?
|
| Migraine Disorders | 1 | 2006 | 64 | 0.060 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 1674 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2006 | 356 | 0.060 |
Why?
|
| Protein Folding | 1 | 2006 | 214 | 0.060 |
Why?
|
| Diagnostic Imaging | 1 | 2007 | 269 | 0.060 |
Why?
|
| UTP-Hexose-1-Phosphate Uridylyltransferase | 1 | 2004 | 5 | 0.060 |
Why?
|
| Galactosemias | 1 | 2004 | 15 | 0.060 |
Why?
|
| Cell Self Renewal | 1 | 2024 | 41 | 0.060 |
Why?
|
| Gene Expression | 1 | 2009 | 1579 | 0.060 |
Why?
|
| Cells, Cultured | 3 | 2021 | 3074 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 751 | 0.060 |
Why?
|
| Alu Elements | 1 | 2004 | 62 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2006 | 747 | 0.050 |
Why?
|
| ADAMTS Proteins | 1 | 2023 | 8 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2004 | 337 | 0.050 |
Why?
|
| Microfluidics | 1 | 2022 | 15 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2009 | 3771 | 0.050 |
Why?
|
| Base Sequence | 1 | 2006 | 3109 | 0.050 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2022 | 112 | 0.050 |
Why?
|
| Alarmins | 1 | 2021 | 4 | 0.050 |
Why?
|
| Developmental Disabilities | 1 | 2006 | 682 | 0.050 |
Why?
|
| DNA | 1 | 2006 | 1606 | 0.040 |
Why?
|
| Cell Death | 1 | 2021 | 241 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2022 | 370 | 0.040 |
Why?
|
| Platelet Count | 1 | 2020 | 130 | 0.040 |
Why?
|
| Syndrome | 2 | 2017 | 1109 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2023 | 523 | 0.040 |
Why?
|
| RNA, Messenger | 1 | 2006 | 2826 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2014 | 12020 | 0.040 |
Why?
|
| Intellectual Disability | 1 | 2006 | 1011 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2021 | 872 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2024 | 3291 | 0.040 |
Why?
|
| Exons | 1 | 2020 | 792 | 0.040 |
Why?
|
| Apolipoprotein L1 | 1 | 2016 | 11 | 0.030 |
Why?
|
| Duffy Blood-Group System | 1 | 2016 | 7 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2024 | 1934 | 0.030 |
Why?
|
| Apolipoproteins | 1 | 2016 | 68 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2019 | 747 | 0.030 |
Why?
|
| Lipoproteins, HDL | 1 | 2016 | 92 | 0.030 |
Why?
|
| Young Adult | 2 | 2023 | 8772 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 2016 | 245 | 0.030 |
Why?
|
| Leukocytes | 1 | 2016 | 204 | 0.030 |
Why?
|
| Receptors, Cell Surface | 1 | 2016 | 469 | 0.030 |
Why?
|
| Neutrophils | 1 | 2016 | 371 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2019 | 797 | 0.030 |
Why?
|
| Middle Aged | 3 | 2023 | 25538 | 0.030 |
Why?
|
| Oncogene Proteins v-myb | 1 | 2013 | 3 | 0.030 |
Why?
|
| Algorithms | 1 | 2020 | 1574 | 0.030 |
Why?
|
| alpha-Thalassemia | 1 | 2013 | 12 | 0.030 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 480 | 0.030 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2013 | 50 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2016 | 542 | 0.030 |
Why?
|
| Glucuronosyltransferase | 1 | 2013 | 70 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2006 | 8096 | 0.030 |
Why?
|
| Bilirubin | 1 | 2013 | 126 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 860 | 0.030 |
Why?
|
| V(D)J Recombination | 1 | 2011 | 6 | 0.020 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2011 | 10 | 0.020 |
Why?
|
| CRADD Signaling Adaptor Protein | 1 | 2009 | 4 | 0.020 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2009 | 6 | 0.020 |
Why?
|
| Apoptotic Protease-Activating Factor 1 | 1 | 2009 | 11 | 0.020 |
Why?
|
| Tubulin Modulators | 1 | 2009 | 10 | 0.020 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2009 | 19 | 0.020 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2009 | 35 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 727 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2009 | 135 | 0.020 |
Why?
|
| Biosensing Techniques | 1 | 2009 | 50 | 0.020 |
Why?
|
| Luminescent Proteins | 1 | 2009 | 157 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2009 | 121 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2009 | 316 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2009 | 347 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2009 | 621 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2009 | 808 | 0.020 |
Why?
|
| RNA Interference | 1 | 2009 | 496 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2011 | 1560 | 0.020 |
Why?
|
| DNA Repair | 1 | 2011 | 583 | 0.020 |
Why?
|
| Kinetics | 1 | 2009 | 1315 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 1076 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2009 | 768 | 0.020 |
Why?
|
| Mitochondria | 1 | 2009 | 666 | 0.010 |
Why?
|
| Ireland | 1 | 2004 | 23 | 0.010 |
Why?
|
| Bacterial Proteins | 1 | 2009 | 874 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 387 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2021 | 15856 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 3296 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 4984 | 0.010 |
Why?
|
| Prognosis | 1 | 2011 | 4484 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2007 | 2441 | 0.010 |
Why?
|
| Diet | 1 | 2007 | 1086 | 0.010 |
Why?
|